Cost effectiveness of pediatric pneumococcal conjugate vaccines: a comparative assessment of decision-making tools (Q33898827)

29 July 2017

title

Cost effectiveness of pediatric pneumococcal conjugate vaccines: a comparative assessment of decision-making tools (English)

1 reference

29 July 2017

1 reference

5

Joachim Hombach

1 reference

29 July 2017

author name string

Nathorn Chaiyakunapruk

1

1 reference

29 July 2017

Ratchadaporn Somkrua

2

1 reference

29 July 2017

Raymond Hutubessy

3

1 reference

29 July 2017

Ana Maria Henao

4

1 reference

29 July 2017

Alessia Melegaro

6

1 reference

29 July 2017

John W Edmunds

7

1 reference

29 July 2017

Philippe Beutels

8

1 reference

29 July 2017

language of work or name

English

0 references

publication date

12 May 2011

1 reference

29 July 2017

1 reference

29 July 2017

volume

9

1 reference

29 July 2017

page(s)

53

1 reference

Cost-effectiveness of pneumococcal conjugate vaccination in Latin America and the Caribbean: a regional analysis

29 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3117724

Cost-effectiveness analyses of vaccination programmes : a focused review of modelling approaches

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3117724

A model for enhancing evidence-based capacity to make informed policy decisions on the introduction of new vaccines in the Americas: PAHO's ProVac initiative

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3117724

Convincing or confusing? Economic evaluations of childhood pneumococcal conjugate vaccination--a review (2002-2006).

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3117724

Need for differential discounting of costs and health effects in cost effectiveness analyses

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3117724

Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3117724

The cost-effectiveness of pneumococcal conjugate vaccination in Australia.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3117724

Decline in Invasive Pneumococcal Disease after the Introduction of Protein–Polysaccharide Conjugate Vaccine

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3117724

Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3117724

Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3117724

A pharmacoeconomic evaluation of seven-valent pneumococcal conjugate vaccine in Spain.

5 July 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-9-53

Cost-effectiveness analysis of a universal vaccination programme with the 7-valent pneumococcal conjugate vaccine (PCV-7) in Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-9-53

Epidemiologic impact and cost-effectiveness of universal infant vaccination with a 7-valent conjugated pneumococcal vaccine in the Netherlands

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-9-53

Combination vaccine against invasive meningococcal B and pneumococcal infections: potential epidemiological and economic impact in the Netherlands.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-9-53

Cost Effectiveness of Pneumococcal Vaccination for Infants and Children with the Conjugate Vaccine PnC-7 in Germany

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-9-53

Benefits and costs of immunization of children with pneumococcal conjugate vaccine in Canada.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-9-53

Enhanced decision support for policy makers using a web interface to health-economic models--illustrated with a cost-effectiveness analysis of nation-wide infant vaccination with the 7-valent pneumococcal conjugate vaccine in the Netherlands.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-9-53

A pharmacoeconomic evaluation of 7-valent pneumococcal conjugate vaccine in Canada.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-9-53

Cost-effectiveness of heptavalent conjugate pneumococcal vaccine (Prevenar) in Germany: considering a high-risk population and herd immunity effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-9-53

Cost-effectiveness of universal pneumococcal vaccination for infants in Italy

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-9-53

The cost-burden of paediatric pneumococcal disease in the UK and the potential cost-effectiveness of prevention using 7-valent pneumococcal conjugate vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-9-53

Cost-effectiveness of pneumococcal conjugate vaccine: evidence from the first 5 years of use in the United States incorporating herd effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-9-53

Invasive meningococcal and pneumococcal disease in Switzerland: cost?utility analysis of different vaccine strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-9-53

The cost-burden of paediatric pneumococcal disease in Sweden and the potential cost-effectiveness of prevention using 7-valent pneumococcal vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-9-53

Cost-effectiveness of pneumococcal conjugate vaccination in the prevention of child mortality: an international economic analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-9-53

Modeling for health care and other policy decisions: uses, roles, and validity

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-9-53

Modeling the impact of a new vaccine on pneumococcal and nontypable Haemophilus influenzae diseases: a new simulation model

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-9-53

Funding of drugs: do vaccines warrant a different approach?

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-9-53

Cost effectiveness analysis of heptavalent pneumococcal conjugate vaccine in Germany considering herd immunity effects

21 January 2018

1 reference

12 December 2020

Modelling the costs and effects of a universal infant immunization program using conjugated pneumococcal vaccine in British Columbia

1 reference

12 December 2020

Cost-effectiveness of a pneumococcal conjugate immunisation program for infants in Switzerland

1 reference

12 December 2020

Pneumococcal pneumonia in the UK--how herd immunity affects the cost-effectiveness of 7-valent pneumococcal conjugate vaccine (PCV)

1 reference

12 December 2020

Cost-benefit and cost-effectiveness of the incorporation of the pneumococcal 7-valent conjugated vaccine in the routine vaccination schedule of Catalonia (Spain)

1 reference

12 December 2020

Economic evaluation of pneumococcal conjugate vaccination in Finland

1 reference

12 December 2020

Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program

1 reference

12 December 2020

Economic evaluation of a universal childhood pneumococcal conjugate vaccination strategy in Ireland

1 reference

12 December 2020

Modelling the effect of conjugate vaccines in pneumococcal disease: cohort or population models?

1 reference

12 December 2020

Identifiers

DOI

10.1186/1741-7015-9-53

1 reference

Dimensions Publication ID

29 July 2017

0 references

1 reference

29 July 2017

1 reference